Coeptis Therapeutics Holdings, Inc. (COEP) is a publicly traded company in the Technology — Software - Services industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.
Analysis Summary
Coeptis Therapeutics Holdings, Inc. reported revenue of $1.4M in the most recent fiscal year, growing at a 5-year CAGR of 113.5%.
Trailing-twelve-month margins: gross margin 86.7%, operating margin -9.6%, net margin -8.7%.
At the current price of $10.99, COEP has negative trailing earnings (P/E not meaningful) and an ROE of -69.09%. Market capitalisation stands at $39M.
Balance sheet quality for COEP: current ratio of 4.2, net cash position of $6.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $10.99 |
| Market Cap | $39M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.50 |
| EV / EBITDA | -5.28 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -69.09% |
| Return on Invested Capital | -71.70% |
| Return on Assets | -60.06% |
| Gross Margin | 86.75% |
| Operating Margin | -956.94% |
| Net Margin | -874.29% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 4.16 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 7.84 |
What to look at in Technology companies
- Revenue growth 3y (>=15%/year) — Validates sustained traction, not a one-off.
- Gross margin (Sub-sector dependent) — SaaS >=70%, Internet >=55%, Semis >=45%, Hardware >=35%.
- FCF / Revenue (>=20%) — Real cash generated. Many tech firms dress up non-GAAP earnings.
- ROIC (>=15%) — Capital reinvested efficiency — Buffett's first metric.
- SBC / Revenue (<10% healthy) — Stock-based compensation. Silent dilution: >20% destroys value.
- Net Debt / EBITDA (<=2x (1.5x SaaS)) — Resilience in downturns and rate hikes.
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| COEP | Coeptis Therapeutics Holdings, Inc. | $39M | 3.50 | -69.1% | |
| 0LP3.L | Verisk Analytics, Inc. | $23.7B | |||
| VRSK | Verisk Analytics, Inc. | $23.2B | 27.88 | 293.9% | |
| CART | Maplebear Inc. | $11.0B | 23.33 | 4.48 | 17.6% |
| BITF.TO | Keel Infrastructure Corp. | $4.7B | 2.34 | -37.2% |
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +15.09% |
| 1 year | +30.16% |
| 3 years | -17.75% |
| 5 years | -91.73% |
52-Week Range
| 52-week High | $21.41 |
| 52-week Low | $6.26 |
| Avg Volume (90d) | 61K |
Related companies: CUE · EQ · IPSC · KPTI · MDCX · NRXP · OSTX
Explore sector: Technology · Software - Services
More sections of COEP: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks